Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Colorectal cancer is the second most common cause of cancer mortality in Western countries. Gene therapy represents a novel approach to the treatment of colorectal cancer, and this review addresses the current strategies and ongoing clinical trials, including gene correction, immunomodulatory approaches and virus-directed enzyme-prodrug systems. Although the pre-clinical results for these strategies have been encouraging, clinical trials have not yet reflected these data. However, gene therapy for colorectal cancer is still in the early stages of development, and its potential, particularly in combination with conventional cancer therapies, warrants further investigation.

Original publication

DOI

10.1016/s1357-4310(99)01598-1

Type

Journal article

Journal

Mol Med Today

Publication Date

02/2000

Volume

6

Pages

82 - 87

Keywords

Animals, Clinical Trials as Topic, Colorectal Neoplasms, Genes, p53, Genes, ras, Genetic Therapy, Humans, Immunotherapy, Active, Prodrugs, Substrate Specificity, Vaccines, Synthetic